Ads
related to: sglt2 inhibitor adverse effects treatment medication information
Search results
Results From The WOW.Com Content Network
The cardioprotective effects of SGLT2 inhibitors have been attributed to the elevated ketone levels. [ 59 ] Gliflozins have been posited to exhibit protective effects on the heart, liver, kidneys, anti‐hyperlipidemic, anti‐ atherosclerotic , anti‐ obesity , anti‐ neoplastic effects in in vitro , pre‐clinical, and clinical studies.
The researchers reviewed 601 published trials of older people to investigate whether the efficacy of three medications — DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 agonists — was affected ...
Bexagliflozin, sold under the brand name Brenzavvy, is an antidiabetic medication used to improve glycemic control in adults with type 2 diabetes. [3] [4] It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken by mouth. [1] [2] The most common side effects include genital yeast infections, urinary tract infections, and increased ...
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor [3] [4] and is in the class of drugs known as gliflozins. [5] In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin. [6]
Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2 inhibitor) used for the treatment of type 2 diabetes mellitus. [1] [2] It was approved for use in Japan in 2014. [1]
Other common side effects include diabetic ketoacidosis, diarrhea, and genital infection in men. [ 2 ] Sotagliflozin was approved for medical use in the European Union in April 2019, as Zynquista , for the treatment for type 1 diabetes , [ 2 ] and in the United States in May 2023, [ 3 ] to reduce the risk of death due to heart failure.